Sugi Predict

Sugi Predict / Compounds / SCHEMBL6931392

SCHEMBL6931392

SCHEMBL6931392

Cn1c(OCCCc2ccccc2)nc(-c2ccncc2)c(-c2ccc(F)cc2)c1=O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 2/20 0.54
▸ MAPK14 Q16539 12/20 0.53
▸ MAOA P21397 2/20 0.48
▸ MAOB P27338 2/20 0.48
▸ MAPK13 O15264 4/20 0.48
▸ MAPK12 P53778 3/20 0.48
▸ MAPK11 Q15759 3/20 0.48
▸ KMT2A Q03164 2/20 0.44
▸ GCGR P47871 1/20 0.44
▸ CYP11B1 P15538 2/20 0.44
▸ CYP11B2 P19099 2/20 0.44
▸ CYP1A2 P05177 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ MAPK9 P45984 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6936912 0.85 MAPK14 (0.54) GSK3BMAPK14MAPK13MAPK12MAPK11
Iodomethane SCHEMBL7238011 0.84 MAPK14 (0.53) GSK3BMAPK14MAPK13MAPK12MAPK11
SCHEMBL6931494 0.82 MAPK14 (0.54) GSK3BMAPK14MAOAMAOBMAPK13
SCHEMBL8327447 0.81 GSK3B (0.53) GSK3BMAPK14MAOAMAOBMAPK13
Dimethylamine SCHEMBL8176050 0.81 MAPK14 (0.52) GSK3BMAPK14MAOAMAOBMAPK13
SCHEMBL6934767 0.77 MAPK14 (0.57) GSK3BMAPK14MAPK13MAPK12MAPK11
SCHEMBL6933665 0.77 MAPK14 (0.50) GSK3BMAPK14MAPK13MAPK12MAPK11
SCHEMBL6933664 0.77 MAPK14 (0.50) GSK3BMAPK14MAPK13MAPK12MAPK11
SCHEMBL27506746 0.77 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11GCGR
Butylamine SCHEMBL6931853 0.76 MAPK14 (0.50) GSK3BMAPK14MAOAMAOBMAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6649604-B2 Analgesics; antidiabetic agents; antiinflamamtory agents AMGEN INC. 2003-11-18 — — US disclosed
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 — — US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 — — US disclosed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 — — US disclosed
EP-0948496-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE Amgen inc. (US) 1999-10-13 — — EP disclosed
WO-1998024780-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073704-A1 Substituted pyridone compounds and methods of use IL6, IL1B, IL1A GSK3B 2369/4885MAPK14 1169/4885MAOA 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.